Akane Kanamori

Suita, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

sPLA2-reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes.

sPLA2-reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes.

Journal: Science advances
Published: July 31, 2026

EBV promotes alveolar trabecula resorption via extracellular vesicle remodeling by group IIA secreted phospholipase A2.

EBV promotes alveolar trabecula resorption via extracellular vesicle remodeling by group IIA secreted phospholipase A2.

Journal: Journal of lipid research
Published: November 08, 2025

Revised model for cell cycle regulation by iron: differential roles between transferrin and ferritin.

Revised model for cell cycle regulation by iron: differential roles between transferrin and ferritin.

Journal: Redox biology
Published: June 06, 2025

Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.

Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.

Journal: Leukemia
Published: January 14, 2024

Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1.

Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1.

Journal: Oncogene
Published: December 26, 2019

EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells.

EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells.

Journal: Scientific reports
Published: October 18, 2019

The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux.

The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux.

Journal: Cell discovery
Published: May 18, 2016

NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells.

NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells.

Journal: Scientific reports
Published: October 11, 2015
Showing 1-8 of 8

Last Updated: 09/26/2026